SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Matt Rourke—AP/REX/Shutterstock

37

Johnson & Johnson

JNJ

The 133-year-old health care conglomerate makes everything from Band-Aids and baby shampoo to contact lenses and hip implants, but its $40.7 billion pharmaceutical division is what drove the most revenue growth in 2018. The company’s cancer and immunology drugs sold especially well. J&J’s medical device division eked out sales growth despite divestitures, as did the company’s consumer business, which continues to see challenges in its recently relaunched baby care line. The company faces more than 13,000 lawsuits—and federal inquiries—over the safety of its talc-based baby powder. (J&J maintains the product is perfectly safe.)

Looking for leads, investment insights, or competitive intelligence?

CEO

Alex Gorsky

CEO Title

Chairman & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

New Brunswick, N.J.

Years on Fortune 500 List

65

Employees

135,100

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$81,5816.7%
Profits ($M)$15,297.01,076.7%
Assets ($M)$152,954
Total Stockholder Equity ($M)$59,752
Profit Ratios
Profit as % of Revenues18.8%
Profits as % of Assets10.0%
Profits as % of Stockholder Equity25.6%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)5.61
EPS % Change (from 2017)1,093.6%
EPS % Change (5 year annual rate)3.1%
EPS % Change (10 year annual rate)2.1%
Total Return
Total Return to Investors (2018)-5.2%
Total Return to Investors (5 year, annualized)10.0%
Total Return to Investors (10 year, annualized)11.3%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Johnson & Johnson

J&J CEO's West Point Lesson: Great Leaders Know How to Listen

CEO Alex Gorsky says his West Point education impacted how he leads at Johnson and Johnson.

Read More →
Xarelto to Become First Prescription Drug With TV Ads That Includes Pricing

There has been government pressure to push all drugmakers into showing prices in ads.

Read More →
Johnson & Johnson and Bayer Settle Xarelto Lawsuits for $775 Million

The drug companies agreed to settle more than 25,000 lawsuits in the U.S. and admit no liability.

Read More →
Jury Awards $29 Million in Latest Johnson & Johnson Cancer-Causing Baby Powder Lawsuit

The lawsuit alleged that the company's talcum-based baby powder contained asbestos.

Read More →